icon-folder.gif   Conference Reports for NATAP  
 
  62th Annual Meeting of the American Association for the Study of Liver Diseases San Francisco 2011 Nov 6-9 Back grey_arrow_rt.gif
 
 
 
Entecavir (ETV) monotherapy for 96 weeks is comparable to combination therapy with ETV plus tenofovir (TDF) in nucleos(t)ide-naïve patients with chronic hepatitis B (CHB): the BE-LOW study
 
 
  Reported by Jules Levin
AASLD Nov 5-9 2011 SF
 
Anna S. Lok1, Huy Trinh2, Giampiero Carosi3, Ulus Akarca4, Adrian Gadano5, François Habersetzer6, William Sievert7, David Wong8, Meghan Lovegren9, David Cohen9, Cyril Llamoso9 1. University of Michigan, Ann Arbor, MI, USA; 2. Pacific Health Foundation, 231 O'Connor Drive, San Jose, CA, USA; 3. Institute of Infectious and Tropical Disease, University of Brescia, Brescia, Italy; 4. Department of Gastroenterology, Faculty of Medicine, Ege University, Izmir, Turkey; 5. Seccion Hepatología, Hospital Italiano de Buenos Aires-Argentina, Ciudad de Buenos Aires, Argentina; 6. Service d'Hepato-gastroentérologie, Nouvel Hopital Civil, 1 Place de l'Hopital, Strasbourg, France; 7. Department of Medicine, Monash University, Monash Medical Centre, Melbourne, Australia; 8. Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada; 9. Research and Development, Bristol-Myers Squibb Company, Wallingford, CT, USA

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif

AASLD12.gif

AASLD13.gif

AASLD14.gif

AASLD15.gif